Literature DB >> 23599159

YWHAE rearrangement identified by FISH and RT-PCR in endometrial stromal sarcomas: genetic and pathological correlations.

Sabrina Croce1, Isabelle Hostein, Agnes Ribeiro, Delphine Garbay, Valérie Velasco, Eberhardt Stoeckle, Frederic Guyon, Anne Floquet, Agnes Neuville, Jean-Michel Coindre, Gaëtan MacGrogan, Frederic Chibon.   

Abstract

Endometrial stromal sarcomas represent the second most common mesenchymal uterine tumor. The 2003 WHO classification distinguishes low-grade and undifferentiated endometrial stromal sarcomas with different prognoses. Endometrial stromal sarcomas are a genetically heterogeneous group of sarcomas harboring different cytogenetic anomalies. Recently, a fusion between the YWHAE and FAM22A/B genes subsequent to a t(10;17) (q22;p13) has been described in endometrial sarcomas with high-grade histology. We examined YWHAE rearrangements by FISH break-apart and RT-PCR in a series of 27 undifferentiated uterine stromal sarcoma without JAZF1 rearrangements. Immunohistochemistry (IHC) was carried out with a panel of antibodies (estrogen (ER) and progesterone (PR) receptors, CD10, Cyclin D1, β-catenin, p53, and Ki-67). We identified a subgroup of endometrial sarcomas with high-grade histology and uniform morphology harboring YWHAE rearrangements. FISH break-apart was interpretable in 20 cases (74%). Twelve cases (60%) showed <10% of tumor cells with a YWHAE rearrangement, 4 cases (20%) showed between 10 and ≤20%, and 4 (20%) >20%. RT-PCR was tested on 24/27 cases (88%) and 19 cases were interpretable (79%). Five cases (26%) showed a specific fusion transcript YWHAE-FAM22A/B sequence. The best concordance rate between FISH and RT-PCR (94%) was obtained with the threshold of 20% of cells with a YWHAE rearrangement. The YWHAE-rearranged cases showed high-grade morphology with uniform appearance, spindle or round epithelioid cells, low ER and PR, CD10 expression, and a high and diffuse positivity for Cyclin D1, p53, and nuclear β-catenin negativity. Cyclin D1 was the most sensitive marker for high-grade endometrial sarcomas with YWHAE rearrangement. All undifferentiated uterine sarcomas with pleomorphic appearances did not harbor any YWHAE rearrangements, except for one case. Overall, for endometrial sarcoma cases with high-grade morphology we recommend to test for YWHAE rearrangements by FISH break-apart, a cost- and time-efficient method, and to complete the investigation by RT-PCR in borderline cases.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23599159     DOI: 10.1038/modpathol.2013.69

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  19 in total

Review 1.  Practical issues related to uterine pathology: endometrial stromal tumors.

Authors:  Marisa R Nucci
Journal:  Mod Pathol       Date:  2016-01       Impact factor: 7.842

Review 2.  Recent advances in the histological and molecular classification of endometrial stromal neoplasms.

Authors:  Joana Ferreira; Ana Félix; Jochen K Lennerz; Esther Oliva
Journal:  Virchows Arch       Date:  2018-10-15       Impact factor: 4.064

3.  Undifferentiated Uterine Sarcomas Represent Under-Recognized High-grade Endometrial Stromal Sarcomas.

Authors:  Paolo Cotzia; Ryma Benayed; Kerry Mullaney; Esther Oliva; Ana Felix; Joana Ferreira; Robert A Soslow; Cristina R Antonescu; Marc Ladanyi; Sarah Chiang
Journal:  Am J Surg Pathol       Date:  2019-05       Impact factor: 6.394

4.  YWHAE-rearranged high-grade endometrial stromal sarcoma: Two-center case series and response to chemotherapy.

Authors:  Matthew L Hemming; Andrew J Wagner; Marisa R Nucci; Sarah Chiang; Lu Wang; Martee L Hensley; Suzanne George
Journal:  Gynecol Oncol       Date:  2017-04-05       Impact factor: 5.482

5.  Pleomorphic high grade endometrial stromal sarcoma with YWHAE gene amplification may be a novel variant with poor prognosis.

Authors:  Asad Ullah; Haritha Arbindi; Francis Zola; Samantha Nieves Mattox; Luis Velasquez Zarate; Janet Munroe; Saleh Heneidi; Suash Sharma; Sharad Ghamande; Daniel T Kleven
Journal:  Int J Clin Exp Pathol       Date:  2022-02-15

Review 6.  [Endometrial and other rare uterine sarcomas : Diagnostic aspects in the context of the 2020 WHO classification].

Authors:  Doris Mayr; Lars-Christian Horn; Grit Gesine Ruth Hiller; Anne Kathrin Höhn; Elisa Schmoeckel
Journal:  Pathologe       Date:  2022-04-01       Impact factor: 1.011

7.  ZC3H7B-BCOR high-grade endometrial stromal sarcomas: a report of 17 cases of a newly defined entity.

Authors:  Natasha Lewis; Robert A Soslow; Deborah F Delair; Kay J Park; Rajmohan Murali; Travis J Hollmann; Ben Davidson; Francesca Micci; Ioannis Panagopoulos; Lien N Hoang; Javier A Arias-Stella; Esther Oliva; Robert H Young; Martee L Hensley; Mario M Leitao; Meera Hameed; Ryma Benayed; Marc Ladanyi; Denise Frosina; Achim A Jungbluth; Cristina R Antonescu; Sarah Chiang
Journal:  Mod Pathol       Date:  2017-12-01       Impact factor: 7.842

8.  Targeted RNA expression profiling identifies high-grade endometrial stromal sarcoma as a clinically relevant molecular subtype of uterine sarcoma.

Authors:  Amir Momeni-Boroujeni; Nissreen Mohammad; Robert Wolber; Stephen Yip; Martin Köbel; Brendan C Dickson; Martee L Hensley; Mario M Leitao; Cristina R Antonescu; Ryma Benayed; Marc Ladanyi; Cheng-Han Lee; Sarah Chiang
Journal:  Mod Pathol       Date:  2020-10-19       Impact factor: 7.842

Review 9.  Potential Therapeutic Targets in Uterine Sarcomas.

Authors:  Tine Cuppens; Sandra Tuyaerts; Frédéric Amant
Journal:  Sarcoma       Date:  2015-10-21

10.  Can proliferation biomarkers reliably predict recurrence in World Health Organization 2003 defined endometrial stromal sarcoma, low grade?

Authors:  Weiwei Feng; Anais Malpica; Ivar Skaland; Einar Gudlaugsson; Stanley J Robboy; Ingvild Dalen; Keqin Hua; Xianrong Zhou; Jan P A Baak
Journal:  PLoS One       Date:  2013-10-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.